Kalinderi, K.; Papaliagkas, V.; Fidani, L. GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease. Int. J. Mol. Sci.2024, 25, 3812.
Kalinderi, K.; Papaliagkas, V.; Fidani, L. GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease. Int. J. Mol. Sci. 2024, 25, 3812.
Kalinderi, K.; Papaliagkas, V.; Fidani, L. GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease. Int. J. Mol. Sci.2024, 25, 3812.
Kalinderi, K.; Papaliagkas, V.; Fidani, L. GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease. Int. J. Mol. Sci. 2024, 25, 3812.
Abstract
Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. Recent data highlight similarities between neurodegenerative diseases including PD and type 2 diabetes mellitus (T2DM) suggesting a crucial interplay between the gut–brain axis. GLP-1R agonists, known for their use in T2DM treatment, are currently extensively studied as novel PD modifying agents. For this narrative review article, we searched PubMed and Scopus databases for peer-reviewed research, review articles and clinical trials regarding GLP-1R agonists and PD, published in the English language with no time restrictions. We also screened the references of the selected articles for possible additional articles in order to include most of the key recent evidence. Our research was conducted between February 2023 and February 2024. We used the terms “GLP-1”, “GLP-1 receptor”, “GLP-1R agonists”, “PD”, “T2DM”, “insulin”, “neurodegenerative disease”, “glucose”, “animal models”, “clinical trials” in different combinations. Many data on animal models and preclinical studies show that GLP1-R agonists can restore dopamine levels, inhibit dopaminergic loss, attenuate neuronal degeneration and alleviate motor and non-motor features of PD. Evidence from clinical studies are also very promising enhancing the possibility of adding GLP1-R agonists in the current armamentarium of drugs available for PD treatment.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
